Evolocumab治疗血脂异常的疗效与安全性的系统评价

钟小燕; 杨旭平; 余彬; 李和教; 黄毅岚

doi:10.13201/j.issn.1001-1439.2016.01.005

Evolocumab治疗血脂异常的疗效与安全性的系统评价

- 1 四川医科大学(四川泸州, 646000);
- 2 泸州医学院附属医院(四川泸州, 646000)

详细信息

通讯作者: 黄毅岚,E-mail:hyl3160131@163.com

中图分类号: R589.21

收稿日期: 2015-08-20

Effect and safety of evolocumab for treating dyslipidemia:a systematic review

- 1 Sichuan Medical University, Sichuan, Luzhou, 646000, China;
- 2 The Affiliated Hospital of Luzhou Medical College

More Information

Corresponding author: HUANG Yilan, E-mail: hyl3160131@163.com

Received Date: 20 August 2015

摘要

摘要: 目的:评价evolocumab治疗血脂异常的疗效与安全性。方法: 计算机检索Medline、Pubmed、Embase、Cochrane图书馆、CNKI、万方、维普等数据库,纳入evolocumab与安慰剂或依折麦布比较的随机对照试验(RCT),利用Stata 12和RevMan 5.3软件对数据进行Meta分析。结果:纳入11篇文献共4 955例患者,Meta分析结果显示:与安慰剂和依折麦布比较,evolocumab能够显著降低LDL-C水平的百分比[安慰剂:-60.87%,95%CI(-64.23,-57.50), P=0.000; 依折麦布:-38.37%, 95%CI(-40.12, -36.63), P=0.000];显著升高HDL-C水平的百分比[安慰剂:6.79%, 95%CI(5.84,7.74), P=0.000;依折麦布:6.79%, 95%CI(5.24, 8.34), P=0.000],并能显著降低TC和TG水平的百分比。在总不良反应发生率方面,两组无显著性差异[RR=1.01, 95%CI(0.92,1.10), P=0.91]。结论: 当前证据显示, evolocumab能有效降低血脂异常患者LDL-C、TC和TG水平和升高HDL-C水平。
- evolocumab /
- 前蛋白转化酶枯草杆菌蛋白酶/溶菌素(PCSK9抑制剂) /
- 血脂异常
Abstract: Objective: To assess the effect and safety evolocumab for dyslipimia. Method: The databases of Medline, Pubmed, Embase, Cochrane Library, CNKI, WangFang, VIP database were retrieved with computers for searching randomized controlled trials comparing evolocumab and placebo or ezetimibe for dyslipidemia. Meta-analysis of the datas were performed by RevMan 5.3 and Stata 13 software. Result: Included 11 RCTs with a total of 4955 patients, comparing with placebo and ezetimibe, evolocumab decreased the percent of LDL-C levels significantly [placebo: -60.87%, 95%CI(-64.23, -57.50), P=0.000; ezetimibe: -38.37%, 95%CI(-40.12, -36.63), P=0.000]; improved the percent of HDL-C levels significantly [placebo: 6.79%, 95%CI (5.84, 7.74), P=0.000; ezetimibe: 6.79%, 95%CI(5.24, 8.34), P=0.000], and reduced the percent of TC and TG levels. The rates of total adverse events between the two groups showed no significant difference[RR=1.01, 95%CI (0.92, 1.10), P=0.91]. Conclusion: The present evidences showed evolocumab was the most effective in reducing LDL-C, TG and TC levels and improved HDL-C levels in dyslipidemia patients.
- evolocumab /
- proprotein convertase subtilisin/kexin type9 /
- dyslipidemia

HTML全文

参考文献(16)

[1]	STONE N J,ROBINSON J G,LICHTENSTEIN A H,et al American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,64:2889-2934.
[2]	中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常指南[J].中华心血管病杂志,2007,35(5):390-419.
[3]	2014年中国胆固醇教育计划血脂异常防治专家建议[J].中华心血管病杂志,2014,8(42),633-636.
[4]	顾智淳,刘晓琰,沈珑,等.前蛋白转化酶枯草溶菌素抑制剂调节血脂的新策略[J].中国新药与临床杂志,2014,9(33):629-634.
[5]	RAAL F J,HONARPOUR N,BLOM D J,et al.Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia(TESLA Part B):a randomised,double-blind,placebo-controlled trial[J].Lancet,2015,385:341-350.
[6]	RAAL F J,STEIN E A,DUFOUR R,et al.PCSK9 inhibition with evolocumab(AMG 145)in heterozygous familial hypercholesterolaemia(RUTHERFORD-2):a randomised,double-blind,placebo-controlled trial[J].Lancet,2015,385:331-340.
[7]	ROBINSON J G,NEDERGAARD B S,ROGERS W J,et al.Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia:the LAPLACE-2randomized clinical trial[J].JAMA,2014,311:1870-1882.
[8]	STROES E,COLQUHOUN D,SULLIVAN D,et al.Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance:the GAUSS-2randomized,placebo-controlled phase 3clinical trial of evolocumab[J].J Am Coll Cardiol,2014,63:2541-2548.
[9]	KOREN M J,LUNDQVIST P,BOLOGNESE M,et al.Anti-PCSK9 monotherapy for hypercholesterolemia:the MENDEL-2randomized,controlled phase III clinical trial of evolocumab[J].J Am Coll Cardiol,2014,63:2531-2540.
[10]	BLOM D J,HALA T,BOLOGNESE M,et al.A 52-week placebo-controlled trial of evolocumab in hyperlipidemia[J].N Engl J Med,2014,370:1809-1819.
[11]	HIRAYAMA A,HONARPOUR N,YOSHIDA M,et al.Effects of evolocumab(AMG 145),a monoclonal antibody to PCSK9,in hypercholesterolemic,statin-treated Japanese patients at high cardiovascular risk-primary results from the phase 2 YUKAWA study[J].Circ J,2014,78:1073-1082.
[12]	GIUGLIANO R P,DESAI N R,KOHLI P,et al.Efficacy,safety,and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9in combination with a statin in patients with hypercholesterolaemia(LAPLACE-TIMI 57):a randomised,placebo-controlled,dose-ranging,phase 2study[J].Lancet,2012,380:2007-2017.
[13]	KOREN M J,SCOTT R,KIM J B,et al.Efficacy,safety,and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9as monotherapy in patients with hypercholesterolaemia(MENDEL):a randomised,double-blind,placebocontrolled,phase 2study[J].Lancet,2012,380:1995-2006.
[14]	RAAL F,SCOTT R,SOMARATNE R,et al.Lowdensity lipoprotein cholesterol-lowering effects of AMG 145,a monoclonal antibody to proprotein convertase subtilisin/kexin type 9serine protease in patients with heterozygous familial hypercholesterolemia:the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder(RUTHERFORD)randomized trial[J].Circulation,2012,126:2408-2417.
[15]	SULLIVAN D,OLSSON A G,SCOTT R,et al.Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients:the GAUSS randomized trial[J].JAMA,2012,308:2497-2506.
[16]	刘兴兰,谷文,雷寒,等.Evolocumab降低低密度脂蛋白胆固醇有效性与安全性的Meta分析[J].临床荟萃,2015,5(30):481-485.